How Long Can Allergan Keep Valeant’s Bid at Bay?

May 12 (Bloomberg) -- Bloomberg’s Drew Armstrong examines Allergan’s rejection of Valeant’s unsolicited offer and actions by the drug maker to find a different buyer other than Valeant. He speaks on Bloomberg Television’s “Market Makers.”
Mila Kunis Helps Miner Become Top Emerald Producer
57:29 - Gemfields CEO Ian Harebottle discusses the gemstone business with Bloomberg's Pimm Fox on "Taking Stock." (Source: Bloomberg)
  • Redfin CEO: How Apple Watch Will Change My Business
  • Is OrangeTheory the Next Big Thing in Fitness Data?
  • Behind the Documentary 'All Eyes and Ears'